Wilden AG located at BioPark Regensburg
Innovations are more than ever the key to success. This is particularly true in the branch of medical technology, to recognise trends early on in the piece and to seize any opportunities for synergism. Rapid links between university and research-intensive start-up companies are a huge advantage here. It is also crucial from a competitive perspective for a system provider such as Wilden to be informed of projects occurring in the industry at the right time. It is with increasing importance that new medical developments are coupled with biotechnology, as seen for example in large pharmaceutical companies working to combat disease who access the biotechnology sector to achieve this. The BioPark is therefore the ideal environment, having its finger right on the pulse regarding new technology and fields of application. As the second largest biotechnology cluster in Bavaria, Regensburg holds enormous potential. In contrast to many other companies following global expansion, Wilden acknowledges itself, as previously, as a company located in Germany. Since its transformation into an AG structured company in 2000, Regensburg has been the headquarters of the Wilden-Group. With 13 production plants and subsidiaries in Europe, the USA and Asia, the AG is one of the largest manufacturers of synthetic material systems for the pharmaceutical and medical technology branches with a turnover of a total of 200 billion € and 1800 employees.
For more information see: